Amplia Therapeutics Limited
Research Amplia Therapeutics Limited (ATX.AX) on Bullrun: market cap AUD 41.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATX.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 41.06M
- Financial periodFY2026
- Net income-AUD 7.71M
- Free cash flow-AUD 8.77M
Valuation Snapshot
latest market cap is AUD 41.06M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | n/a | -AUD 7.71M | -AUD 8.77M | n/a | -0.02 | AUD 27.85M | AUD 341.11K | AUD 39.47M |
| FY2025 | n/a | -AUD 6.57M | -AUD 6.89M | n/a | -0.02 | AUD 10.86M | AUD 13.89K | AUD 21.02M |
| FY2024 | n/a | -AUD 4.50M | -AUD 5.13M | n/a | -0.02 | AUD 3.39M | AUD 1.59M | AUD 11.42M |
| FY2023 | n/a | -AUD 6.24M | -AUD 5.31M | n/a | -0.03 | AUD 9.26M | AUD 2.28M | AUD 15.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 41.06M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Amplia Therapeutics Limited
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Amplia Therapeutics Limited's market cap?
Amplia Therapeutics Limited's market capitalization is AUD 41.06M.
What does Amplia Therapeutics Limited do?
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018.